don't be dissapointed, much to look forward to

I sense that some may be dissapointed that the SP has not met their expectation following DNDN's approval. There has been no "explosion" in PRR's share price.

I am definetly not dissapointed. PRR is a long term investment which requires patience.

ON THE 22APRIL I POSTED:
"I have gone along with the popular belief that a positive FDA decision for Dendreon will result in a share price rerating for Prima.

However, will this in fact be the case?

Perhaps the only thing that will cause a re-rating of the PRR share price will be more boxes being ticked on the way to commercialisation.

E.g.,
Orphan status decision/s.
Trials progress reports.
Takeover interest.
Nasdaq listing.

I am preparing myself for the possibility that the Dendreon FDA decision will not have any impact on PRR -either way. If it was going to, it should have done so already. Afterall, the speculation of a positive decision for Dendreon has been going on and on for several months and has been reflected in an increasing share price. Not so with Prima".